Table 1.

Methylation of CpGs of HPV16, 18, 31 and 45 and DAPK amplicons and statistical evaluations.

	Methylated CpGs in L2/L1	Percent of methylated CpG in L2/L1 per sample	Methylated CpGs in DAPK	Percent of methylated CpGs in DAPK per sample
HPV16 (63 samples)	N/total	Mean (SE)	N/total	Mean (SE)
Asymptomatic	5/50 (10.0%)	8.3 (9.2)	6/48 (12.5%)	12.5 (12.7)
ASCUS	11/90 (12.2%)	12.2 (7.6)	7/72 (9.7%)	9.7 (10.4)
LSIL/CIN1	19/140(13.6%)	13.6 (6.1)	26/112 (23.2%)	23.2 (8.3)
HSIL/CIN2-3	67/210 (31.9%)	31.9 (4.9)	46/168 (27.4%)	27.4 (6.8)
Invasive cancer	108/130 (83.1%)	83.1 (6.3)	57/104 (54.8%)	58.7 (8.6)
p-value	p < 0.0005^a	p < 0.0005^b	p < 0.0005^a	p=0.004^b
HPV18 (14 samples)
Asymptomatic	0/28 (0.0%)	0.0 (8.1)	1/16 (6.3%)	6.3 (15.1)
ASCUS	5/42 (11.9%)	11.9 (6.6)	0/56 (0.0%)	0.0 (12.3)
LSIL/CIN1	7/28 (25.0%)	25.0 (8.1)	3/16 (18.8%)	18.8 (15.1)
HSIL/CIN2-3	21/28 (75.0%)	75.0 (8.1)	3/16 (18.8%)	18.8 (15.1)
Invasive cancer	56/70 (80.0%)	81.4 (5.1)	31/40 (77.5%)	77.5 (9.6)
p-value	p < 0.0005^a	p < 0.0005^b	p < 0.0005^a	p=0.004^b
HPV31 (15 samples)
Asymptomatic	0/18 (0.0%)	0.0 (16.1)	0/8 (0.0%)	0.0 (26.2)
ASCUS	3/54 (5.6%)	5.6 (9.3)	1/24 (4.2%)	4.2 (15.2)
LSIL/CIN1	11/54 (20.4%)	20.4 (9.3)	4/24 (16.7%)	16.7 (15.2)
HSIL/CIN2-3	39/72 (54.2%)	54.2 (8.1)	3/32 (9.4%)	9.4 (13.1)
Invasive cancer	35/72 (48.6%)	48.6 (8.1)	20/32 (62.5%)	62.5 (13.1)
p-value	p < 0.0005^a	p=0.008^b	p < 0.0005^a	p=0.064^b
HPV45 (12 samples)
Asymptomatic	0/18 (0.0%)	0.0 (15.6)	0/8 (0.0%)	0.0 (28.0)
ASCUS	N/A	N/A	N/A	N/A
LSIL/CIN1	0/18 (0.0%)	0.0 (15.6)	1/8 (12.5%)	12.5 (28.0)
HSIL/CIN2-3	59/72 (81.9%)	81.9 (7.8)	5/32 (15.6%)	15.6 (14.0)
Invasive cancer	102/108 (94.4%)	94.4 (6.4)	38/48 (79.2%)	79.2 (11.4)
p-value	p < 0.0005^a	p=0.001^b	p < 0.0005^a	p=0.021^b

SE: standard error.

Chi-square test for trend.

F-test.